ADVERSE PROGNOSTIC FACTORS FOR THE CATHETER ISOLATION OF PULMONARY VEINS OSTIA EFFICACY IN PAROXYSMAL ATRIAL FIBRILLATION WITH NO ORGANIC HEART PATHOLOGY (THE PRUF STUDY)

Aim. To investigate on the prediction factors and main parameters of patients that influence catheter isolation of pulmonary veins ostia (PVO) in paroxysmal atrial fibrillation (AF) with no organic pathology of the heart. Material and methods. The PRUF study is single-center, prospective, comparison, open, randomized trial with control group. Subanalysis of PRUF reported, that included total efficacy of catheter ablation of PVO in one or two procedures, with comparison of prediction factors and main characteristics of the included patients, that influence outcomes. Totally, 243 patients were included after effective catheter isolation of PVO. Of those 142 (58,44%) were males, 101 (41,56%) females, mean age — 56,09±10,14 y.o. with arrhythmia anamnesis 4,48±2,6 years. Efficacy of operation was assessed based on the analysis of registered rhythm disorder episodes by subcutaneous ECG registration, Holter monitoring and standard ECG. Results. In a year of follow-up after catheter ablation of PVO the overall efficacy was 66,6%, n=162, 95% confidence interval (CI) 61-72%; after the two 88,5%, n=215, 95% CI 84-92%. After one procedure: mean age of non-affective patients was 53,3±10,67 vs 57,48±9,6 y.o. of effective (p=0,002). In comparison of echo parameters of the left atrium diameter (LA) in non-effective was 4,22±0,28 vs 4,12±0,27 in effective (p=0,007). By the comorbidities: arterial hypertension (p=0,35), chronic heart failure (p=0,64), diabetes (p=0,57) there were no difference, however by thyroid gland there was significant difference in hypothyroidism in anamnesis (p=0,033). Comparing the same properties after two procedures: mean age of non-effective was 54,32±10,12 vs 57,09±9,62 y.o. of effective (p=0,18), LA diameter in non-effective 4,28±0,29 vs 4,11±0,27 in effective (p=0,004). For thyroid pathology, there was also significant difference in hypothyroidism in anamnesis in non-effective group 32,14% vs 10,19% effective (p=0,005) and by hyperthyroidism in anamnesis 7,14% vs 2,78% (p=0,011). Conclusion. The LA size is a prediction factor for the efficacy of catheter PVO in paroxysmal AL patients with no organic pathology of the heart (p<0,005). Younger patients needed more repeated interventions for an effective outcome (p=0,002 after one isolation of PVO and p=0,18 after the two). From the comorbidities, as an adverse factor of efficacy there was thyroid pathology in anamnesis, in either one or two interventions.

atrial fibrillation, radiofrequency ablation of the pulmonary veins ostia, early post-surgery period, verapamil, propafenon, sotalol, the PRUF study

1. Diagnostics and management of atrial fibrillation. RSC and RNSA guidelines, 2012. Russian Cardiological Journal 2013; 4(102), app. 3: 6-7, 61-76. Russian (Диагностика и лечение фибрилляции предсердий. Рекомендации РКО и ВНОА, 2012. Российский кардиологический журнал 2013; 4(102), приложение 3: 6-7, 61-76).

2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 Esc Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the ESC. Developed with the special contribution of the EHRA of the ESC. Endorsed by the ESO. European Heart Journal DOI:10.1093/eurheartj/ehw210.

3. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation — a translational appraisal. Physiol Rev 2010; 11:45-49.

4. Pappone E, Rosanio S, Oreto G, et al. Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia A New Anatomic Approach for Curing Atrial Fibrillation Carlo. Circulation 2000; 102:2619-28.

5. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14(4): 528-606.

6. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. Jan 27 2010; 303(4):333–340.

7. Tarasov A.V., Davtyan K.V., Martsevich S.Yu., Shatakhtsyan V.S. Prevention of atrial tachyarrhythmia in post-operation period of pulmonary veins ostia catheter isolation in paroxysmal atrial fibrillation. Cardiovascular Therapy and Prevention, 2016; 15(5): 43-49 Russian (Тарасов А.В., Давтян К.В., Марцевич С.Ю., Шатахцян В.С. Профилактика предсердных тахиаритмий в послеоперационном периоде катетерной изоляции устьев легочных вен у пациентов с пароксизмальной формой фибрилляции предсердий. Кардиоваскулярная терапия и профилактика 2016; 15(5), 43-49).

8. Tarasov A.V., Davtyan K.V., Miller O.N., Shatakhtsyan V.S.The efficacy of antiarrhythmic therapy in the early postoperative period of catheter isolation of the mouths of the pulmonary veins for the treatment of paroxysmal atrial fibrillation. Consilium medicum, 2016; 18 (12): 49-54 Russian (Тарасов А.В., Давтян К.В., Миллер О.Н., Шатахцян В.С. Эффективность антиаритмической терапии в раннем послеоперационном периоде катетерной изоляции устьев легочных для лечения пароксизмальной формы фибрилляции предсердий. Consilium medicum [Профилактическая медицина] 2016; №12/ том18, С 49-54).

9. Arya A, Hindricks G, Sommer P, et al. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace. Feb 2010; 12(2):173–180.

10. Balk EM, Garlitski AC, Alsheikh-Ali AA, Terasawa T, Chung M, Ip S. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic re review. J Cardiovasc Electrophysiol. Nov 2010; 21(11): 1208 –1216.

11. McCready JW, Smedley T, Lambiase PD, et al. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. Europace. Mar 2011; 13(3): 355–361.

12. Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update. Eur Heart J 2014; 35: 2454–9.

13. Elesin D.A., Romanov A.B., Turov A.N., et al. Radiofrequency ablation of paraxysmal and prolonged persistent atrial fibrillation: one-year follow-up with the use of continuous subcutaneous monitoring. Journal of Arrhythmology. 2011; 63: 5-11 Russian (Елесин Д.А., Романов А.Б., Туров А.Н. и др. Радиочастотная аблация пароксизмальной и длительно персистирующей форм фибрилляции предсердий: 1-летний период наблюдения с помощью непрерывного подкожного мониторирования. Вестник аритмологии 2011; 63, 5-11).